Celldex Therapeutics, Inc. — Director's Dealing 2020

Jun 19, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2020-06-18

Reporting Person: Martin Samuel Bates (SVP and CFO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-06-18	Incentive Stock Option (right to buy)	$10.38	A	105600	Acquired	2030-06-18	Common Stock (105600)	Direct

Footnotes

F1: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan.

F2: 25% vest on June 18, 2021 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.